骨髓瘤骨病的发生机制及治疗进展

[1]	王辰,王建安,黄从新,等.内科学[M].3版.北京:人民卫生出版社,2015:863-872.
[2]	胡豫,孙春艳.多发性骨髓瘤的诊断进展[J].临床血液学杂志,2012,25(7):406-409.
[3]	李斯丹,徐燕,邱录贵,等.多发性骨髓瘤骨病的临床特点分析[J].中华血液学杂志,2010,31(4):228-232.
[4]	褚彬,陆敏秋,吴梦青,等.多发性骨髓瘤骨病临床特点及监测骨代谢标志物的临床意义[J].中华医学杂志,2016,96(18):1424-1429.
[5]	O'Donnell EK,Raje NS.Myeloma bone disease:pathogenesis and treatment[J].Clin Adv Hematol Oncol,2017,15:285-295.
[6]	Dotterweich J,Schlegelmilch K,Keller A,et al.Contact of myeloma cells induces a characteristic transcripotome signature in skeletal precursor cells-implications for myeloma bone disease[J].Bone,2016,93:155-166.
[7]	Ishiyama K,Yashiro T,Nakano N,et al.Involvement of PU.1 in NFATc1 promoter function in osteoclast development[J].Allergol Int,2015,64:241-247.
[8]	Kim HJ,Kang WY,Seong SJ.Follistatin-like 1 promotes osteoclast formation via RANKL mediated NF-κB activation and M-CSF-induced precursor proliferation[J].Cell Signal,2016,28:1137-1144.
[9]	Lamothe B.TRAF6 ubiquitin ligase is essential for RANKL signaling and osteoclast differentiation[J].Biochem Biophys Res Commun,2007,359:1044-1049.
[10]	Sun CY,Chu ZB,She XM,et al.Brain-derived neurotrophic factor is a potential osteoclast stimulating factor in multiple myeloma[J].Int J Cancer,2012,130:827-836.
[11]	Yaghoobi MM,Mowla SJ.Differential gene expression pattern of neurotrophins and their receptors during neuronal differentiation of rat bone marrow stromal cells[J].Neurosci Lett,397:149-154.
[12]	Kumamaru E,Numakawa T,Adachi N,et al.Glucocorticoid suppresses BDNF-stimulated MAPK/ERK pathway via inhibiting interaction of Shp2 with TrkB[J].FEBS Lett,2011,585:3224-3228.
[13]	张萌萌.生命、骨骼、维生素D3[J].中国骨质疏松杂志,2016,22(11):1496-1500.
[14]	Masih-Khan E,Trudel S,Heise C,et al.MIP-1alpha (CCL3) is a downstream target of FGFR3 and RAS-MAPK signaling in multiple myeloma[J].Blood,2006,108:3465-3471.
[15]	Lentzsch S,Gries M,Janz M,et al.Macrophage inflammatory protein 1-alpha (MIP-1 alpha) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells[J].Blood,2003,101:3568-3573.
[16]	Vallet S,Pozzi S,Patel K,et al.A novel role for CCL3(MIP-1α) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function[J].Leukemia,2011,25:1174-1181.
[17]	彭凤平,付蓉,刘惠,等.血清骨代谢物检测在骨髓瘤骨病诊断和病情监测中的意义[J].中华医学杂志,2015,95(42):3436-3439.
[18]	Eda H,Santo L,Wein MN,et a1.Regulation of sclerostin expression in multiple myeloma by Dkk-1:A potential therapeutic strategy for myeloma bone disease[J].J Bone Miner Res,2016,31:1225-1234.
[19]	Walker RE,Lawson MA,Buckle CH,et al.Myeloma bone disease:pathogenesis,current treatments and future targets[J].Br Med Bull,2014,111:117-138.
[20]	冯晓燕,邓书会,安刚,等.血清DKK1检测在多发性骨髓瘤及其骨病中的应用[J].中华血液学杂志,2015,36(8):682-685.
[21]	Kaiser M,Mieth M,Liebisch P,et al.Serum con-centrations of DKK-1 correlate with the extent of bone disease in patients with multiple myeloma[J].Eur J Haematol,2008,80:490-494.
[22]	马军.多发性骨髓瘤骨病的预防及治疗[J].中华血液学杂志,2013,34(4):292-294.
[23]	中华医学会血液学分会.多发性骨髓瘤骨病诊治指南[J].中华血液学杂志,2011,32(10):721-723.
[24]	Terpos E,Sezer O,Croucher P,et al.Myeloma bone disease and proteasome inhibition therapies[J].Blood,2007,110:1098-1104.
[25]	高珊,付蓉,邵宗鸿.成骨细胞与骨髓瘤骨病[J].临床血液学杂志,2014,27(22):994-997.
[26]	鲍立,卢锡京,张晓辉,等.不同治疗方案对多发性骨髓瘤患者骨病的影响[J].中华血液学杂志,2011,32(4):221-225.
[27]	Terpos E,Mihou D,Szydlo R,et al.The combination of intermediate doses of thalidomide with dexamethasone is an effective treatment for patients with refractory/relapsed multiple myeloma and normalizes abnormal bone remodeling,through the reduction of sRANKL/osteoprotegerin ratio[J].Leukemia,2005,19:1969-1976.
[28]	Henry DH,Costa L,Goldwasser F,et al.Randomized,double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma[J].J Clin Oncol,2011,29:1125-1132.
[29]	Yaccoby S,Ling W,Zhan F,et al.Antibody based inhibition of DKK1 suppresses tumor-induced bone resorption and multiple myeloma growth in vivo[J].Blood,2007,109:2106-2111.
[30]	Vallet S,Raje N,Ishitsuka K,et al.MLN3897,a novel CCR1 inhibitor,impairs osteoclastogenesis and inhibits the interaction of multiple myeloma cells and osteoclasts[J].Blood,2007,110:3744-3752.